Search Results - "McLeod, David G"

Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens by Miki, Jun, Furusato, Bungo, Li, Hongzhen, Gu, Yongpeng, Takahashi, Hiroyuki, Egawa, Shin, Sesterhenn, Isabell A, McLeod, David G, Srivastava, Shiv, Rhim, Johng S

“…Understanding normal and cancer stem cells may provide insight into the origin of and new therapeutics for prostate cancer. Normal and cancer stem cells in…”
Get full text

Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men by Farrell, James, Petrovics, Gyorgy, McLeod, David G, Srivastava, Shiv

“…Prostate cancer is the most common non-skin cancer and the second leading cause of cancer-related death for men in the United States. Prostate cancer incidence…”
Get full text

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer by Kiebish, Michael A, Cullen, Jennifer, Mishra, Prachi, Ali, Amina, Milliman, Eric, Rodrigues, Leonardo O, Chen, Emily Y, Tolstikov, Vladimir, Zhang, Lixia, Panagopoulos, Kiki, Shah, Punit, Chen, Yongmei, Petrovics, Gyorgy, Rosner, Inger L, Sesterhenn, Isabell A, McLeod, David G, Granger, Elder, Sarangarajan, Rangaprasad, Akmaev, Viatcheslav, Srinivasan, Alagarsamy, Srivastava, Shiv, Narain, Niven R, Dobi, Albert

“…Predicting the clinical course of prostate cancer is challenging due to the wide biological spectrum of the disease. The objective of our study was to identify…”
Get full text

Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression by Gesztes, William, Schafer, Cara, Young, Denise, Fox, Jesse, Jiang, Jiji, Chen, Yongmei, Kuo, Huai-Ching, Mwamukonda, Kuwong B., Dobi, Albert, Burke, Allen P., Moul, Judd W., McLeod, David G., Rosner, Inger L., Petrovics, Gyorgy, Tan, Shyh-Han, Cullen, Jennifer, Srivastava, Shiv, Sesterhenn, Isabell A.

“…TP53 is one of the most frequently altered genes in prostate cancer. The precise assessment of its focal alterations in primary tumors by immunohistochemistry…”
Get full text

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia by Kiebish, Michael A., Tekumalla, Poornima, Ravipaty, Shobha, Dobi, Albert, Srivastava, Shiv, Wu, Wenfang, Patil, Saurabh, Friss, Tracey, Klotz, Allison, Srinivasan, Alagarsamy, Cullen, Jennifer, Rosner, Inger L., Ali, Amina, Laszlo, Sandra, Petrovic, Michele, Fleshner, Neil, Garren, Jeonifer, Miller, Greg, Mahaveer Chand, Nischal, Rodrigues, Leonardo O., Granger, Elder, Kellogg, Mark D., Luan, Shen, Diamandis, Eleftherios, Akmaev, Viatcheslav R., Sarangarajan, Rangaprasad, Bountra, Chas, Freedland, Stephen J., McLeod, David G., Narain, Niven R.

“…Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic…”
Get full text

Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes by Brassell, Stephen A, Rice, Kevin R, Parker, Patrick M, Chen, Yongmei, Farrell, James S, Cullen, Jennifer, McLeod, David G

“…Currently there is a lack of consensus on screening recommendations for prostate cancer with minimal guidance on the cessation of screening in older men. We…”
Get more information

A Feedback Loop between the Androgen Receptor and a NEDD4-binding Protein, PMEPA1, in Prostate Cancer Cells by Li, Hongyun, Xu, Linda L., Masuda, Katsuaki, Raymundo, Eliza, McLeod, David G., Dobi, Albert, Srivastava, Shiv

“…PMEPA1 was identified originally as a highly androgen-inducible gene with prostate-abundant expression that was restricted to prostatic epithelial cells…”
Get full text

Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy by AMLING, Christopher L, RIFFEBURGH, Robert H, CHUNG, Andrew K, MCLEOD, David G, SUN, Leon, MOUL, Judd W, LANCE, Raymond S, KUSUDA, Leo, SEXTON, Wade J, SODERDAHL, Douglas W, DONAHUE, Timothy F, FOLEY, John P

“…To determine if obesity is associated with higher prostate specific antigen recurrence rates after radical prostatectomy (RP), and to explore racial…”
Get full text

Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers by Sharad, Shashwat, Allemang, Travis C, Li, Hua, Nousome, Darryl, Ku, Anson Tai, Whitlock, Nichelle C, Sowalsky, Adam G, Cullen, Jennifer, Sesterhenn, Isabell A, McLeod, David G, Srivastava, Shiv, Dobi, Albert

“…Prostate cancer incidence in young men has increased. Patients diagnosed at an earlier age are likely to have aggressive prostate cancer and treatment…”
Get full text

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy by Moul, Judd W, Wu, Hongyu, Sun, Leon, McLeod, David G, Amling, Christopher, Donahue, Timothy, Kusuda, Leo, Sexton, Wade, O'Reilly, Keith, Hernandez, Javier, Chung, Andrew, Soderdahl, Douglas

“…Hormonal therapy (HT) is the current mainstay of systemic treatment for prostate specific antigen (PSA) only recurrence (PSAR), however, there is virtually no…”
Get more information

Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression by POMERANTZ, Mark M, BECKWITH, Christine A, STAMPFER, Meir J, CHANT, Jennifer A, ARDLIE, Kristin G, FRITZ, Brian R, PARKIN, Rachael K, LIN, Daniel W, DYKE, Michelle, HERMAN, Paula, LEE, Steve, OH, William K, REGAN, Meredith M, KANTOFF, Philip W, TEWARI, Muneesh, MCLEOD, David G, SRIVASTAVA, Shiv, FREEDMAN, Matthew L, WYMAN, Stacia K, PETROVICS, Gyorgy, YONGMEI CHEN, HAWKSWORTH, Dorota J, SCHUMACHER, Fredrick R, MUCCI, Lorelei, PENNEY, Kathryn L

“…Polymorphisms at 8q24 are robustly associated with prostate cancer risk. The risk variants are located in nonprotein coding regions and their mechanism has not…”
Get full text

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men by Petrovics, Gyorgy, Li, Hua, Stümpel, Tanja, Tan, Shyh-Han, Young, Denise, Katta, Shilpa, Li, Qiyuan, Ying, Kai, Klocke, Bernward, Ravindranath, Lakshmi, Kohaar, Indu, Chen, Yongmei, Ribli, Dezső, Grote, Korbinian, Zou, Hua, Cheng, Joseph, Dalgard, Clifton L., Zhang, Shimin, Csabai, István, Kagan, Jacob, Takeda, David, Loda, Massimo, Srivastava, Sudhir, Scherf, Matthias, Seifert, Martin, Gaiser, Timo, McLeod, David G., Szallasi, Zoltan, Ebner, Reinhard, Werner, Thomas, Sesterhenn, Isabell A., Freedman, Matthew, Dobi, Albert, Srivastava, Shiv

“…Evaluation of cancer genomes in global context is of great interest in light of changing ethnic distribution of the world population. We focused our study on…”
Get full text

Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer by YING HU, DOBI, Albert, MOHAMED, Ahmed, CHEN SUN, SESTERHENN, Isabell A, MCLEOD, David G, PETROVICS, Gyorgy, SRIVASTAVA, Shiv, SREENATH, Taduru, COOK, Christopher, TADASE, Atekelt Y, RAVINDRANATH, Lakshmi, CULLEN, Jennifer, FURUSATO, Bungo, YONGMEI CHEN, THANGAPAZHAM, Rajesh L

“…Purpose: The expression of the ETS -related gene ( ERG ) is low or undetectable in benign prostate epithelial cells. High prevalence of ERG overexpression in…”
Get full text

Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer by Metwalli, Adam R., M.D, Rosner, Inger L., M.D, Cullen, Jennifer, Ph.D., M.P.H, Chen, Yongmei, M.D, Brand, Timothy, M.D, Brassell, Stephen A., M.D, Lesperance, James, M.D, Porter, Christopher, M.D, Sterbis, Joseph, M.D, McLeod, David G., M.D

“…Abstract Objectives In patients with a rising prostate-specific antigen (PSA) level during treatment with androgen deprivation therapy, identification of men…”
Get full text

The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma by Tsunoda, Toshiyuki, Furusato, Bungo, Takashima, Yasuo, Ravulapalli, Suma, Dobi, Albert, Srivastava, Shiv, McLeod, David G., Sesterhenn, Isabell A., Ornstein, David K., Shirasawa, Senji

“…BACKGROUND Three‐dimensional culture (3DC) is a relevant in vitro model used to study prostate development and carcinogenesis. Recent studies have indicated…”
Get full text

Health-related quality of life for men with prostate cancer—an evaluation of outcomes 12–24 months after treatment by Brassell, Stephen A., M.D, Elsamanoudi, Sally I., M.P.H, Cullen, Jennifer, Ph.D, Williams, Molly E., M.D, McLeod, David G., M.D., J.D

“…Abstract Objective To determine the health-related quality of life (HRQoL) impact of prostate cancer interventions at 2 years post-treatment, and between the…”
Get full text

Prostate-Specific Antigen Nadir and Cancer-Specific Mortality Following Hormonal Therapy for Prostate-Specific Antigen Failure by STEWART, Alexandra J, SCHER, Howard I, CHEN, Ming-Hui, MCLEOD, David G, CARROLL, Peter R, MOUL, Judd W, D'AMICO, Anthony V

“…For men receiving androgen-suppression therapy (AST) for a rising postoperative or postradiation prostate-specific antigen (PSA), we evaluated whether a PSA…”
Get full text

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens by Crawford, E. David, Schellhammer, Paul F., McLeod, David G., Moul, Judd W., Higano, Celestia S., Shore, Neal, Denis, Louis, Iversen, Peter, Eisenberger, Mario A., Labrie, Fernand

“…Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on…”
Get full text

Low risk prostate cancer in men ≥ 70 years old: To treat or not to treat by Rice, Kevin R., M.D, Colombo, Monica L., M.D, Wingate, Jonathan, M.D, Chen, Yongmei, M.D., M.P.H, Cullen, Jennifer, Ph.D., M.P.H, McLeod, David G., M.D., J.D, Brassell, Stephen A., M.D

“…Abstract Objectives Prostate cancer (CaP) in the aging male will become an increasingly important and controversial health care issue. We evaluated the…”
Get full text

ERG oncogene modulates prostaglandin signaling in prostate cancer cells by Mohamed, Ahmed A., Tan, Shyh-Han, Sun, Chen, Shaheduzzaman, Syed, Hu, Ying, Petrovics, Gyorgy, Chen, Yongmei, Sesterhenn, Isabell A., Li, Hua, Sreenath, Taduru, McLeod, David G., Dobi, Albert, Srivastava, Shiv

“…Androgen dependent induction of the ETS related gene (ERG) expression in more than half of all prostate cancers results from gene fusions involving regulatory…”
Get full text